Biomarkers [low-density lipoprotein–cholesterol, glial fibrillary acidic protein (GFAP), lipoprotein-associated phospholipase A2, antibodies against NR2A/NR2B subunits of the N-Methyl-D-Aspartate (NMDA) receptor, neuron-specific enolase, myelin basic protein, heart-type fatty acid-binding protein—HFABP, Parkinson’s disease protein 7—PARK7, and nucleoside diphosphate kinase A—NDKA] that have the potential to distinguish stroke from diseases mimicking stroke or from healthy controls have been proposed in many studies aiming to measure their levels in the blood [31,32,33,34]. This evidence concerns the gene NME1 and stroke disorder.